The 650-microsecond pulse duration delivers high-powered energy in an ultra-short burst, allowing precise targeting of melanin, hemoglobin, and water without excessive thermal damage. This enables safe treatment across all Fitzpatrick skin types (I-VI), including darker skin tones that risk hyperpigmentation with longer pulse durations used by traditional lasers.

Most practices achieve ROI within 6-12 months. With acne treatments priced at $200-400 per session and patients requiring 4-6 treatments, a single patient can generate $2,400-$3,600 in revenue. The Neo Elite treats 36+ FDA-approved indications, allowing you to treat multiple indications anywhere on the body, creating multiple revenue streams from one device investment.

Aerolase differentiates from Cutera, Candela, and Cynosure through its proprietary 650-microsecond pulse technology that emphasizes regenerative aesthetics rather than controlled tissue destruction. Unlike competitors requiring cooling systems (Candela's cryogen spray, Cutera's sapphire cooling), Aerolase treatments are virtually painless with no anesthetics or consumables, reducing operating costs. The Neo Elite treats 36+ FDA-cleared indications with one handpiece and is safe for all Fitzpatrick skin types (I-VI), while competitors often require multiple devices—Alexandrite for lighter skin and Nd:YAG for darker skin. While Candela and Cynosure excel at high-volume hair removal with larger spot sizes (up to 28mm) and faster treatment speeds, and Cutera's Excel V+ dominates vascular-focused treatments with dual wavelengths, Aerolase positions as the innovative choice for practices seeking a versatile, patient-friendly platform that stimulates natural collagen production across diverse treatment applications without the consumable costs and complexity of legacy laser systems.

Yes, Aerolase devices are FDA-cleared for 36+ indications including acne vulgaris, rosacea, pseudofolliculitis barbae, melasma, benign pigmented lesions, vascular lesions, wrinkles, scars, onychomycosis, psoriasis, and verrucae. This broad clearance allows practices to address multiple patient concerns with a single platform.

Absolutely. Aerolase is specifically designed for safe treatment of all Fitzpatrick skin types (I-VI) with minimal risk of post-inflammatory hyperpigmentation. The 650-microsecond pulse duration and lack of epidermal contact eliminate the burning and PIH risks commonly associated with other laser treatments on darker skin.

Yes, Aerolase complements existing services including injectables (Botox, fillers), chemical peels, microneedling, and skincare protocols. The device enhances overall skin quality and is often incorporated into combination treatment packages. Many practitioners use it as a foundation treatment before or alongside injectables for superior results.

There is essentially no downtime with Aerolase. Patients may experience mild, transient redness immediately following treatment that typically resolves within hours. No crusting, peeling, or social downtime occurs, allowing patients to return to work and normal activities immediately—a significant advantage over ablative or traditional laser treatments.